NGL Fine-Chem Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Latest quarter profit grew 99.1% YoY, showing strong momentum
- Company has consistently been profitable over the last 5 years
- Company comfortably covers its interest (13.4x coverage)
- Working capital cycle has improved - days down from 114 to 92
- Company has a consistent dividend-paying track record
- Company maintains a comfortable, low leverage position
CONS
- Receivables are growing faster than sales - a possible quality concern
- Free cash flow has been persistently negative
- Total debt has risen sharply - up 58.5% year on year
- Company has delivered a poor profit growth of -3.2% over past five years
- Though reporting repeated profits, the company pays out little dividend (2.2%)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1864.00 | 36.98 | 447236.04 | 0.86 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9405.00 | 85.36 | 249673.20 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4928.40 | 85.95 | 187460.49 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1118.00 | 24.71 | 111520.93 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1380.00 | 33.08 | 111484.47 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1936.00 | 95.67 | 104604.45 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1669.00 | 25.87 | 96030.57 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| DRREDDY | 1140.80 | 29.55 | 95220.28 | 0.70 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| LUPIN | 2075.00 | 17.16 | 94882.67 | 0.87 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2246.00 | 45.42 | 92769.93 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2417.00 | 37.94 | 68213.70 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| NGLFINE | 2720.25 | 29.38 | 1680.58 | 0.06 | 18.40 | 99.08 | 139.16 | 33.57 | 16.88 | 16.73 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 71 | 80 | 88 | 100 | 91 | 93 | 89 | 95 | 104 | 120 | 128 | 149 | 139 | |
| 61 | 66 | 74 | 84 | 81 | 82 | 84 | 89 | 93 | 103 | 105 | 128 | 122 | |
| Operating Profit | 10 | 14 | 14 | 16 | 9 | 12 | 5 | 6 | 11 | 17 | 22 | 21 | 17 |
| OPM % | 13.88% | 17.42% | 15.77% | 15.86% | 10.30% | 12.36% | 5.72% | 6.65% | 10.54% | 14.27% | 17.50% | 14.35% | 12.25% |
| 3 | 3 | 4 | 4 | 6 | 5 | -0 | -1 | 6 | 2 | 5 | 2 | 7 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 | 5 |
| Profit before Tax | 10 | 14 | 14 | 16 | 12 | 13 | 1 | 1 | 12 | 13 | 21 | 18 | 24 |
| Tax % | 15.67% | 24.82% | 30.01% | 23.43% | 21.80% | 26.41% | -0.79% | 49.06% | 21.96% | 25.77% | 24.09% | 24.31% | 24.84% |
| Net Profit | 0 | 0 | 0 | 0 | 9 | 10 | 1 | 1 | 9 | 10 | 16 | 13 | 18 |
| 13.77 | 16.96 | 16.24 | 19.95 | 14.92 | 15.88 | 2.07 | 0.88 | 14.96 | 15.58 | 25.40 | 21.83 | 29.78 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 153 | 152 | 258 | 318 | 278 | 339 | 368 | 501 | 536 | |
| 121 | 132 | 178 | 249 | 243 | 285 | 333 | 428 | 458 | |
| Operating Profit | 32 | 20 | 80 | 68 | 35 | 54 | 35 | 73 | 78 |
| OPM % | 21.08% | 13.03% | 31.05% | 21.48% | 12.57% | 15.87% | 9.45% | 14.64% | 14.53% |
| 4 | 3 | 8 | 11 | 6 | 14 | 9 | 15 | 17 | |
| Interest | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 5 | 4 |
| Depreciation | 6 | 8 | 8 | 10 | 11 | 12 | 12 | 20 | 21 |
| Profit before Tax | 28 | 12 | 78 | 67 | 27 | 54 | 28 | 63 | 76 |
| Tax % | 26.99% | 30.96% | 26.90% | 25.08% | 25.09% | 24.07% | 23.78% | 24.05% | 24.67% |
| Net Profit | 20 | 8 | 57 | 50 | 20 | 41 | 21 | 48 | 57 |
| EPS | 0.00 | 13.49 | 91.81 | 80.77 | 33.18 | 66.63 | 34.19 | 77.90 | — |
| Dividend Payout % | 5.37% | 13.32% | 1.91% | 2.17% | 5.30% | 2.63% | 5.12% | 2.25% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 14%
- 3 Years:
- 22%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- -3%
- 3 Years:
- 33%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 11%
- 1 Year:
- 86%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 16%
- 3 Years:
- 14%
- Last Year:
- 16%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 89 | 96 | 151 | 200 | 219 | 260 | 279 | 326 | |
| 24 | 23 | 11 | 27 | 31 | 33 | 75 | 112 | |
| Trade Payables | 16 | 21 | 30 | 37 | 25 | 49 | 52 | 65 |
| 17 | 11 | 12 | 10 | 9 | 11 | 32 | 55 | |
| Total Liabilities | 149 | 154 | 207 | 277 | 287 | 356 | 442 | 560 |
| 61 | 68 | 64 | 89 | 88 | 86 | 143 | 164 | |
| Capital Work in Progress | 0 | 0 | 12 | 6 | 26 | 46 | 50 | 95 |
| 9 | 11 | 29 | 29 | 39 | 54 | 60 | 39 | |
| 19 | 28 | 38 | 56 | 27 | 43 | 51 | 70 | |
| 0 | 0 | 0 | 0 | 0 | 90 | 83 | 131 | |
| Cash & Bank | 3 | 3 | 5 | 1 | 13 | 2 | 5 | 5 |
| 58 | 44 | 59 | 96 | 93 | 36 | 51 | 56 | |
| Total Assets | 149 | 154 | 207 | 277 | 287 | 356 | 442 | 560 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 16 | 24 | 48 | 31 | 42 | 20 | 32 | 43 | |
| Cash from Investing | -10 | -20 | -25 | -14 | -27 | -27 | -70 | -71 |
| Cash from Financing | 0 | -1 | -1 | -1 | -1 | -1 | 37 | 30 |
| -1 | -0 | 2 | -1 | 7 | -7 | 0 | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-10 - NGL Fine-Chem Limited has informed the Exchange about Schedule of meet
2026-08-27 - NGL Fine-Chem Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 25, 2026. Further, the company has informed the Exchange regarding voting results.
2026-08-25 - NGL Fine-Chem Limited has informed the Exchange regarding Proceedings of undefined held on August 25, 2026
2026-08-20 - NGL Fine-Chem Limited has informed the Exchange regarding Corrigendum to the 45th Annual Report for the Financial Year 2025-2026
2026-08-17 - NGL Fine-Chem Limited has informed the Exchange about Investor Presentation
2026-08-14 - NGL Fine-Chem Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-12 - NGL Fine-Chem Limited has informed the Exchange regarding 'Board comments on fines levied by the Exchanges'.
2026-08-12 - Outcome of Board Meeting
2026-08-12 - NGL Fine-Chem Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
News
Recent coverage and analyst commentary for NGLFINE
Loading news…
AI Stock Analyst
NGL Fine-Chem Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account